Company History Timeline — 2020s
2020
必威体育登录手机Agilent receives FDA approval for PD-L1 IHC 22C3 pharmDx in Triple-Negative Breast Cancer, marking the seventh cancer type for which the companion diagnostic gains approval in the US.
必威体育登录手机Agilent launches its first-ever instrument subscription program, becoming a leader in lab customer excellence and technology services delivery.It also introduces CrossLab Connect services for lab-wide asset monitoring and the 7850 ICP-MS System that improves ICP-MS analysis workflows.
必威体育登录手机Agilent is one of the earliest champions and sponsors of My Green Lab, a nonprofit organization that provides certified sustainability labels to lab instruments, giving customers insight into the environmental footprint of their purchases.
Net revenue: $5.34 billion!employees: 16,400.
2021
必威体育登录手机Agilent launches three InfinityLab Bio LC systems, completing a solution of instruments, columns, and supplies that seamlessly integrate with Agilent OpenLab and MassHunter software, and CrossLab services.必威体育登录手机This further maximizes the efficiency of Agilent's biopharma customers.
必威体育登录手机For a third consecutive year, Agilent is ranked in the top three of Barron's Most Sustainable Companies in America, a distinction that recognizes environmental leadership in our operations, our products, and our supply chain.
必威体育登录手机Agilent names Katharine Knobil, M.D., the company's first chief medical officer, a newly created position to advise, lead, and elevate Agilent's presence in the heath-care industry.
必威体育登录手机Agilent and Visopharm expand their collaboration with a worldwide distribution agreement, marking Agilent's first entry into the growing digital pathology market by leveraging artificial intelligence and remote reporting capabilities.
必威体育登录手机Building on decades of corporate social responsibility initiatives and public reporting, Agilent commits to reaching net-zero emissions by 2050.
2022
必威体育登录手机Agilent introduces the 6475 triple quadrupole LC/MS system, 5977C GC/MSD, 7000E GC/TQ and 7010C GC/TQ, representing a significant advancement in Agilent's 50-plus year history in mass spectrometry.必威体育赛事投注The new LC/TQ and GC/TQ products offer built-in instrument intelligence to simplify lab operations.必威体育赛事投注The new GC/SQ and GC/TQ products with the HydroInert source help customers overcome performance challenges with hydrogen carrier gas.
必威体育登录手机Agilent continues to expand its end-to-end lab solutions by acquiring powerful AI and machine learning software for GC/MS platforms, and hardware and software solutions for the analysis of natural and synthetic polymers.
必威体育登录手机Agilent is ranked among the top 20 companies in customer satisfaction by the Wall Street Journal's list of the 250 Best-Managed Companies.
2023
必威体育登录手机Agilent announces a doubling of manufacturing capacity of nucleic acid-based therapeutics to meet growing demand for the company's high-quality therapeutic oligonucleotides that serve as the API for drugs that target diseases such as cancer, cardiovascular disease, and rare and infectious diseases.
必威体育登录手机Agilent achieves Great Place to Work® certification in all countries and territories eligible for the distinction, including the U.S.An overwhelming majority of employees indicate a strong level of satisfaction with the company.
必威体育登录手机Agilent releases a full workflow for targeted PFAS analysis, a solution that brings substantial efficiency gains to a labor-intensive testing process.The solution comes at a critical time of growing concern about the buildup of PFAS in the environment.